FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017612047> ?p ?o ?g. }

• W2017612047 endingPage "5390" @default.
• W2017612047 startingPage "5384" @default.
• W2017612047 abstract "Abstract In this phase 1/2 study, we explored the feasibility and activity of an oral regimen of lenalidomide with low-dose dexamethasone and low-dose oral cyclophosphamide (RdC) in patients with primary systemic light chain amyloidosis. RdC was given for up to 12 cycles in prespecified cohorts at escalated doses: 13 patients were treated in phase 1 and 24 in phase 2; 65% were previously untreated, and most had renal and/or cardiac involvement and elevated cardiac biomarkers. Lenalidomide 15 mg/d and cyclophosphamide 100 mg/d were further evaluated in phase 2. On intention to treat, 20 (55%) patients achieved a hematologic response, including 3 (8%) complete remissions. Hematologic responses were seen at all dose levels and in 4 of 5 patients who had received bortezomib previously. An organ response was recorded in 22% of patients on intention-to-treat and in 40% of patients who survived at least 6 months. The median time to progression was 10 months and the 2-year survival was 41%. Fatigue, nonneutropenic infections, and rash were the most common toxicities. The results of the present study show that RdC is an oral regimen with activity in primary systemic light chain amyloidosis and may be an additional treatment option, especially for patients with preserved organ function or for patients who cannot receive or who relapse after bortezomib. This study is registered at www.clinicaltrials.gov as NCT00981708." @default.
• W2017612047 created "2016-06-24" @default.
• W2017612047 creator A5000544577 @default.
• W2017612047 creator A5006370598 @default.
• W2017612047 creator A5024471527 @default.
• W2017612047 creator A5037373686 @default.
• W2017612047 creator A5041407463 @default.
• W2017612047 creator A5049136237 @default.
• W2017612047 creator A5054453797 @default.
• W2017612047 creator A5057945564 @default.
• W2017612047 creator A5072987204 @default.
• W2017612047 creator A5084290492 @default.
• W2017612047 creator A5088691462 @default.
• W2017612047 creator A5091600816 @default.
• W2017612047 date "2012-06-07" @default.
• W2017612047 modified "2023-10-14" @default.
• W2017612047 title "A phase 1/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis" @default.
• W2017612047 cites W1994394328 @default.
• W2017612047 cites W1995859732 @default.
• W2017612047 cites W2008608243 @default.
• W2017612047 cites W2013789617 @default.
• W2017612047 cites W2026585322 @default.
• W2017612047 cites W2029409133 @default.
• W2017612047 cites W2034372485 @default.
• W2017612047 cites W2036497786 @default.
• W2017612047 cites W2037490796 @default.
• W2017612047 cites W2041167176 @default.
• W2017612047 cites W2054091101 @default.
• W2017612047 cites W2077918440 @default.
• W2017612047 cites W2092074428 @default.
• W2017612047 cites W2092679212 @default.
• W2017612047 cites W2098093182 @default.
• W2017612047 cites W2107403553 @default.
• W2017612047 cites W2137477100 @default.
• W2017612047 cites W2143756652 @default.
• W2017612047 cites W2151246487 @default.
• W2017612047 cites W2161231801 @default.
• W2017612047 cites W2163260428 @default.
• W2017612047 cites W2169336006 @default.
• W2017612047 cites W4238487952 @default.
• W2017612047 doi "https://doi.org/10.1182/blood-2011-12-396903" @default.
• W2017612047 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22517904" @default.
• W2017612047 hasPublicationYear "2012" @default.
• W2017612047 type Work @default.
• W2017612047 sameAs 2017612047 @default.
• W2017612047 citedByCount "85" @default.
• W2017612047 countsByYear W20176120472012 @default.
• W2017612047 countsByYear W20176120472013 @default.
• W2017612047 countsByYear W20176120472014 @default.
• W2017612047 countsByYear W20176120472015 @default.
• W2017612047 countsByYear W20176120472016 @default.
• W2017612047 countsByYear W20176120472017 @default.
• W2017612047 countsByYear W20176120472018 @default.
• W2017612047 countsByYear W20176120472019 @default.
• W2017612047 countsByYear W20176120472020 @default.
• W2017612047 countsByYear W20176120472021 @default.
• W2017612047 countsByYear W20176120472022 @default.
• W2017612047 countsByYear W20176120472023 @default.
• W2017612047 crossrefType "journal-article" @default.
• W2017612047 hasAuthorship W2017612047A5000544577 @default.
• W2017612047 hasAuthorship W2017612047A5006370598 @default.
• W2017612047 hasAuthorship W2017612047A5024471527 @default.
• W2017612047 hasAuthorship W2017612047A5037373686 @default.
• W2017612047 hasAuthorship W2017612047A5041407463 @default.
• W2017612047 hasAuthorship W2017612047A5049136237 @default.
• W2017612047 hasAuthorship W2017612047A5054453797 @default.
• W2017612047 hasAuthorship W2017612047A5057945564 @default.
• W2017612047 hasAuthorship W2017612047A5072987204 @default.
• W2017612047 hasAuthorship W2017612047A5084290492 @default.
• W2017612047 hasAuthorship W2017612047A5088691462 @default.
• W2017612047 hasAuthorship W2017612047A5091600816 @default.
• W2017612047 hasBestOaLocation W20176120471 @default.
• W2017612047 hasConcept C126322002 @default.
• W2017612047 hasConcept C141071460 @default.
• W2017612047 hasConcept C159654299 @default.
• W2017612047 hasConcept C203014093 @default.
• W2017612047 hasConcept C2776063141 @default.
• W2017612047 hasConcept C2776364478 @default.
• W2017612047 hasConcept C2776694085 @default.
• W2017612047 hasConcept C2776755627 @default.
• W2017612047 hasConcept C2777478702 @default.
• W2017612047 hasConcept C2778570526 @default.
• W2017612047 hasConcept C2778674544 @default.
• W2017612047 hasConcept C2779551797 @default.
• W2017612047 hasConcept C2779609412 @default.
• W2017612047 hasConcept C2779951007 @default.
• W2017612047 hasConcept C2780401358 @default.
• W2017612047 hasConcept C2780648854 @default.
• W2017612047 hasConcept C2780945303 @default.
• W2017612047 hasConcept C2781413609 @default.
• W2017612047 hasConcept C31760486 @default.
• W2017612047 hasConcept C36394416 @default.
• W2017612047 hasConcept C71924100 @default.
• W2017612047 hasConcept C90924648 @default.
• W2017612047 hasConceptScore W2017612047C126322002 @default.
• W2017612047 hasConceptScore W2017612047C141071460 @default.
• W2017612047 hasConceptScore W2017612047C159654299 @default.
• W2017612047 hasConceptScore W2017612047C203014093 @default.

• next